New Frontiers of Cardiovascular Diseases Management – “Preclinical and Clinical Strategies”

Dear Colleagues,

Cardiovascular pathologies constitute a serious and important socio-economic burden. Diseases of the heart and of the vascular system are the leading cause of death worldwide. In the Western world, the number of people at high risk of cardiovascular disease is steadily increasing, but about half of these are unaware of their risk status. This phenomenon intensifies the risk, because it makes it invisible and therefore does not allow the deployment of all the tools necessary to contain complications and implement appropriate therapeutic initiatives. The management and prevention of cardiovascular diseases represents a great challenge for the health care system. The progression of preclinical and clinical knowledge is of fundamental importance. Knowing the pathophysiological mechanisms and their management will allow the progressive improvement of clinical-therapeutic medical skills.

On this basis, we invite investigators to contribute original research as well as review articles addressing the identification of novel preclinical and clinical findings to manage cardiovascular diseases. This will improve our knowledge of the possible therapeutic approaches and create new opportunities to improve patients’ outcome.

Potential topics include but are not limited to the following:

- Identification of novel molecules and mechanisms involved in the onset and progression of cardiovascular diseases;

- Novel potential therapeutic approaches to reduce the onset of cardiovascular diseases;

- Identification of novel management strategies to prevent cardiovascular diseases;

- Discovery of novel clinical and pharmacological approaches to slow cardiovascular disease progression.

Dr. Albino Carrizzo
Dr. Paola Di Pietro
Dr. Carmine Izzo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• identification of novel molecules and mechanisms involved in the onset and progression of cardiovascular diseases
• novel potential therapeutic approaches to reduce the onset of cardiovascular diseases
• identification of novel management strategies to prevent cardiovascular diseases
• discovery of novel clinical and pharmacological approaches to slow cardiovascular disease progression